- Home
- ROOT vs OCUL Comparison
ROOT vs OCUL Comparison
Compare ROOT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- OCUL
- Stock Information
- Founded
- ROOT 2015
- OCUL 2006
- Country
- ROOT United States
- OCUL United States
- Employees
- ROOT N/A
- OCUL N/A
- Industry
- ROOT Property-Casualty Insurers
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- OCUL Health Care
- Exchange
- ROOT Nasdaq
- OCUL Nasdaq
- Market Cap
- ROOT 2.3B
- OCUL 2.3B
- IPO Year
- ROOT 2020
- OCUL 2014
- Fundamental
- Price
- ROOT $80.94
- OCUL $11.26
- Analyst Decision
- ROOT Buy
- OCUL Strong Buy
- Analyst Count
- ROOT 6
- OCUL 9
- Target Price
- ROOT $130.60
- OCUL $22.13
- AVG Volume (30 Days)
- ROOT 488.8K
- OCUL 3.2M
- Earning Date
- ROOT 10-29-2025
- OCUL 11-13-2025
- Dividend Yield
- ROOT N/A
- OCUL N/A
- EPS Growth
- ROOT N/A
- OCUL N/A
- EPS
- ROOT 4.73
- OCUL N/A
- Revenue
- ROOT $1,364,700,000.00
- OCUL $56,664,000.00
- Revenue This Year
- ROOT $27.41
- OCUL N/A
- Revenue Next Year
- ROOT $9.74
- OCUL $18.87
- P/E Ratio
- ROOT $17.31
- OCUL N/A
- Revenue Growth
- ROOT 59.76
- OCUL N/A
- 52 Week Low
- ROOT $36.87
- OCUL $5.79
- 52 Week High
- ROOT $181.14
- OCUL $13.85
- Technical
- Relative Strength Index (RSI)
- ROOT 33.20
- OCUL 41.98
- Support Level
- ROOT $89.55
- OCUL $10.85
- Resistance Level
- ROOT $92.27
- OCUL $11.77
- Average True Range (ATR)
- ROOT 4.42
- OCUL 0.72
- MACD
- ROOT -1.30
- OCUL -0.16
- Stochastic Oscillator
- ROOT 1.57
- OCUL 28.63
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.